Advanced Non-Human Primate (NHP) Antibody Humanization Service

Background Platform Workflow Advantage Related Services FAQ Online Inquiry

Non-human primate (NHP) models, particularly cynomolgus and rhesus macaques, represent the gold standard in preclinical evaluation for many novel biologic drugs due to their profound physiological and immunological similarity to humans. Antibodies developed or validated in these models offer a highly predictive assessment of therapeutic potential. However, despite high sequence homology (typically >95%), subtle yet critical differences in framework regions (FRs) can elicit an anti-drug antibody (ADA) response in human patients, compromising safety and efficacy. At Creative Biolabs, with over 20 years of leadership in antibody engineering, our Non-Human Primate (NHP) Antibody Humanization service meticulously re-engineers your candidate antibody, eliminating potential immunogenic epitopes while rigorously preserving its binding affinity, specificity, and therapeutic function.

Discuss Your Project Today

The NHP Advantage and the Humanization Imperative

NHP-derived antibodies are invaluable because they often recognize human orthologs with functionally equivalent activity and affinity. This makes them superior candidates for humanization compared to rodent antibodies.

Feature	Murine Antibody	Non-Human Primate (NHP) Antibody	Human Antibody
Sequence Homology to Human	~80-85%	>95%	100%
Immunogenicity Risk	High	Low to Moderate	None (Theoretic)
Framework Mismatches	Numerous	Few, but critical	None
Humanization Requirement	Essential	Highly Recommended for Clinical Success	Not Applicable
Predictive Value	Moderate	High	Not Applicable

Even a few amino acid differences in the framework regions can be recognized as foreign by the human immune system. Our service is designed to systematically identify and replace these residues with their human germline counterparts, effectively "cloaking" the antibody to evade immune detection.

Our State-of-the-Art NHP Antibody Humanization Platform

Creative Biolabs employs a multi-faceted, technology-driven approach that goes beyond simple CDR grafting. Our platform integrates computational biology with proven molecular engineering techniques to guarantee optimal results.

Fig. 1 Humanization methods. (OA Literature) Fig. 1 Humanization methods have evolved from initial chimerization approaches, aiming to reduce non-humanness without compromising functionality.¹

Comprehensive 3D Structural Analysis & In Silico Modeling

The foundation of our service is a deep, structure-based understanding of your antibody.

Homology Modeling: We generate high-resolution 3D models of your NHP antibody's variable fragment.
Canonical Structure Analysis: We precisely identify the Conformational Determining Residues (CDRs) and the Specificity Determining Residues (SDRs)—the critical subset of CDRs that make direct contact with the antigen.
FR Residue Impact Assessment: Our proprietary algorithms analyze each NHP framework residue, predicting its potential contribution to CDR conformation, VH-VL interface stability, and overall structural integrity. This allows us to pinpoint which "Vernier zone" and other key FR residues must be retained to preserve function.

Intelligent Human Acceptor Framework Selection

We utilize a comprehensive human germline database to select the most suitable acceptor framework. Our selection process is based on:

Maximum Homology: Choosing the human framework with the highest sequence identity to the NHP parent.
CDR Canonical Structure Matching: Ensuring the chosen human framework supports the original CDR loop conformation.
Low Immunogenicity Profile: Selecting frameworks known to have low potential for generating an immune response.

Advanced CDR & SDR Grafting Strategies

We offer a range of grafting strategies tailored to your project's specific needs:

Classic CDR Grafting: The standard approach of transplanting all six CDRs onto the selected human framework.
Targeted SDR Grafting: A more refined technique where only the essential SDRs are grafted. This approach minimizes the amount of non-human sequence, thereby further reducing immunogenicity risk.

Meticulous Back-Mutation & Optimization

A direct graft can sometimes lead to a loss of affinity. Our experts meticulously analyze the 3D model to identify key NHP framework residues that are crucial for maintaining the optimal CDR conformation. Through a rational design process, we introduce a minimal number of critical "back-mutations" to the human framework, effectively restoring or even enhancing the original antibody's affinity and stability.

Workflow of NHP Antibody Humanization

Our process is structured, transparent, and collaborative, ensuring you are informed at every stage.

Phase 1: In-depth Analysis and Strategic Design

Sequencing of the NHP antibody variable domains (VH and VL).
Generation of high-fidelity 3D structural models.
Selection of optimal human acceptor frameworks.
Design of multiple humanized variants, including different grafting strategies and back-mutation profiles.
Comprehensive design report delivered to the client for review and selection.

Phase 2: Molecular Construction and Expression

Codon-optimized gene synthesis for the designed humanized variants.
Subcloning into our high-yield mammalian expression vectors.
Transient expression in HEK293 or CHO cells.
High-purity antibody protein purification.

Phase 3: Rigorous Biophysical Validation

Affinity Measurement: Binding kinetics and affinity analysis using Surface Plasmon Resonance (SPR) or Bio-Layer Interferometry (BLI) to confirm affinity preservation.
Specificity Testing: ELISA or flow cytometry to ensure binding to the target antigen is maintained.
Thermal Stability Assessment: Differential Scanning Calorimetry (DSC) to confirm the stability of the humanized constructs.
Final Report: A comprehensive report detailing all design, expression, and validation data, empowering you to select the lead clinical candidate.

Advantages of Choosing Creative Biolabs for NHP Antibody Humanization

Unparalleled Expertise: Leverage our 20+ years of dedicated experience in antibody engineering.

Guaranteed Affinity Preservation: Our primary goal is to deliver humanized antibodies with affinity comparable to or better than the parental NHP antibody.
Maximized Immunogenicity Reduction: Our advanced structural analysis and minimal back-mutation strategy ensure the lowest possible immunogenicity risk.
High-Throughput Capacity: We can design, produce, and screen multiple humanized candidates in parallel to identify the optimal version.
Customized Strategies: We don't believe in a one-size-fits-all solution. Your project receives a tailored strategy based on its unique structural and functional requirements.
Complete Downstream Support: Seamlessly transition to our other services, including affinity maturation, large-scale production, and stability studies.

Explore Our Comprehensive Antibody Services

To further advance your therapeutic antibody program, Creative Biolabs offers a comprehensive suite of integrated services:

Ready to move your NHP antibody toward the clinic? Trust the experts at Creative Biolabs to deliver a meticulously engineered, low-immunogenicity, high-affinity clinical candidate.

Contact Us Today for a Free Quote!

Frequently Asked Questions (FAQs)

Q: Why is it necessary to humanize a Non-Human Primate (NHP) antibody if its sequence is already over 95% identical to human antibodies?

A: While the sequence homology is high, the remaining 1-5% differences, primarily in the framework regions, can contain T-cell and B-cell epitopes. These can trigger an anti-drug antibody (ADA) response in patients, leading to reduced efficacy, altered pharmacokinetics, and potential adverse events. Professional humanization mitigates this risk significantly.

Q: What is the typical timeline for an NHP antibody humanization project?

A: A standard project, from sequence receipt to delivery of purified, validated antibody candidates, typically takes between 8 and 12 weeks. This timeline can be adjusted based on project complexity.

Q: How do you ensure the binding affinity is not lost during the humanization process?

A: Our structure-based approach is key. By creating a high-resolution 3D model, we understand the interplay between the framework and the CDR loops. This allows us to perform rational back-mutations, re-introducing only the most critical parental NHP residues needed to maintain the CDRs' antigen-binding conformation. All candidates are then experimentally validated for affinity using SPR or BLI.

Q: What starting material do I need to provide?

A: The ideal starting material is the DNA or amino acid sequence of the variable heavy (VH) and light (VL) chains of your NHP antibody. If you only have the hybridoma cell line or purified antibody protein, we can perform antibody sequencing as an initial step.

Reference

Gordon, Gemma L., et al. "Prospects for the computational humanization of antibodies and single domain antibodies." Frontiers in Immunology 15 (2024): 1399438. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2024.1399438

×

Online Inquiry

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.